Physician profile
Celeste B Hart
NPI 1932212263
$466.50
in general payments reported to CMS, 2019-2025
8 companies · $55.92 in 2025
The $55.92 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.24 · 2020: $32.27 · 2021: $29.36 · 2022: $30.19 · 2023: $137 · 2024: $102 · 2025: $55.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.17 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $111.25 | 2021-2025 | Omnipod |
| Beta Bionics, INC. | $84.70 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascensia Diabetes Care US INC. | $83.10 | 2023 | |
| Novo Nordisk INC | $78.47 | 2020-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $66.12 | 2019 | |
| Tandem Diabetes Care, INC. | $17.42 | 2022 | |
| Abbott Laboratories | $13.12 | 2019 | |
| Medtronic, INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.